anifrolumab   Click here for help

GtoPdb Ligand ID: 8258

Synonyms: MDX-1333 | MEDI-546
Immunopharmacology Ligand
Compound class: Antibody
Comment: Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), being developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. [3]. Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences patented with application US7662381 [3]. The sequence matches identify anifrolumab as clone 11E2 in the patent.
Click here for help
Immunopharmacology Comments
Anifrolumab acts to block IFNα binding to its cognate receptor, thereby preventing IFNAR1 activation.
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
Phase 3 clinical candidate for SLE.
Scleroderma Disease Ontology: DOID:419
Clinical candidate for scleroderma.